FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382516616> ?p ?o ?g. }

• W4382516616 abstract "Abstract Background We investigated evolocumab’s real-world effectiveness and safety on a background of statin therapy in the acute phase of ischemic stroke (IS) patients with a very high-risk of atherosclerotic cardiovascular disease (ASCVD). Methods A real-world, single-center, retrospective study was conducted in the neurology department at Tianjin Huanhu Hospital in China. Patients were divided into two groups: evolocumab treatment (140 mg every two weeks) or the standard of care (SOC) group. The primary efficacy outcome of the study was the achievement of a targeted lipid control rate and the incidence of major adverse cardiovascular events (MACE) by the end of the follow-up. Propensity score matching (PSM) analysis was utilized to account for confounding factors between groups. Survival analysises were performed using the Kaplan-Meier method. Results 1080 AIS patients with very high-risk ASCVD were recruited. After PSM, there were 528 individuals, with 206 in the evolocumab group and 322 in the standard of care (SOC) group. At 12 months of follow-up, the proportion of LDL-C < 1.4mmol/L and ≥50% reduction was 44.9% in the evolocumab group, compared with only 3.1% of SOC-treated patients ( p = 0.000). The median follow-up time for clinical events was 15 months. The evolocumab group was associated with a lower risk of cerebrovascular events compared to the SOC group (HR, 0.45; 95% CI, 0.23-0.89; p = 0.022) but did not significantly reduce the incidence of cardiovascular events (HR, 0.51; 95% CI, 0.17-1.51; p = 0.224), event-related deaths (HR, 0.71; 95% CI, 0.34-1.46; p = 0.349), or MACE (HR, 0.71; 95% CI, 0.44-1.06; p = 0.089). Conclusions This real-world study suggested that evolocumab on a background of statin reduced the LDL-C levels significantly with a well-tolerated profile and lowered the incidence of recurrent cerebrovascular events in the very high-risk ASCVD patients with AIS in China." @default.
• W4382516616 created "2023-06-30" @default.
• W4382516616 creator A5002379126 @default.
• W4382516616 creator A5015640756 @default.
• W4382516616 creator A5046395881 @default.
• W4382516616 creator A5056636897 @default.
• W4382516616 creator A5062301213 @default.
• W4382516616 creator A5081489339 @default.
• W4382516616 creator A5086433908 @default.
• W4382516616 creator A5088174174 @default.
• W4382516616 creator A5088445624 @default.
• W4382516616 date "2023-06-29" @default.
• W4382516616 modified "2023-10-16" @default.
• W4382516616 title "Real-World Effectiveness and Safety of Evolocumab in Very High-risk Atherosclerotic Cardiovascular Disease Patients with Acute Ischemic Stroke" @default.
• W4382516616 cites W1433049918 @default.
• W4382516616 cites W1520609538 @default.
• W4382516616 cites W2016095885 @default.
• W4382516616 cites W2087400134 @default.
• W4382516616 cites W2115619413 @default.
• W4382516616 cites W2116764523 @default.
• W4382516616 cites W2138595885 @default.
• W4382516616 cites W2153274104 @default.
• W4382516616 cites W2164089346 @default.
• W4382516616 cites W2410405995 @default.
• W4382516616 cites W2563893819 @default.
• W4382516616 cites W2596179513 @default.
• W4382516616 cites W2801826551 @default.
• W4382516616 cites W2809611706 @default.
• W4382516616 cites W2888988297 @default.
• W4382516616 cites W2908290318 @default.
• W4382516616 cites W2944133085 @default.
• W4382516616 cites W2945916227 @default.
• W4382516616 cites W2966658839 @default.
• W4382516616 cites W2968156277 @default.
• W4382516616 cites W2970625233 @default.
• W4382516616 cites W2988991070 @default.
• W4382516616 cites W3016856494 @default.
• W4382516616 cites W3017084496 @default.
• W4382516616 cites W3028287257 @default.
• W4382516616 cites W3034297742 @default.
• W4382516616 cites W3080103475 @default.
• W4382516616 cites W3080801838 @default.
• W4382516616 cites W3082719615 @default.
• W4382516616 cites W3100110041 @default.
• W4382516616 cites W3190767999 @default.
• W4382516616 cites W4211152466 @default.
• W4382516616 cites W4293171433 @default.
• W4382516616 cites W4323666205 @default.
• W4382516616 cites W4324392923 @default.
• W4382516616 doi "https://doi.org/10.1101/2023.06.25.23291877" @default.
• W4382516616 hasPublicationYear "2023" @default.
• W4382516616 type Work @default.
• W4382516616 citedByCount "0" @default.
• W4382516616 crossrefType "posted-content" @default.
• W4382516616 hasAuthorship W4382516616A5002379126 @default.
• W4382516616 hasAuthorship W4382516616A5015640756 @default.
• W4382516616 hasAuthorship W4382516616A5046395881 @default.
• W4382516616 hasAuthorship W4382516616A5056636897 @default.
• W4382516616 hasAuthorship W4382516616A5062301213 @default.
• W4382516616 hasAuthorship W4382516616A5081489339 @default.
• W4382516616 hasAuthorship W4382516616A5086433908 @default.
• W4382516616 hasAuthorship W4382516616A5088174174 @default.
• W4382516616 hasAuthorship W4382516616A5088445624 @default.
• W4382516616 hasBestOaLocation W43825166161 @default.
• W4382516616 hasConcept C118552586 @default.
• W4382516616 hasConcept C120665830 @default.
• W4382516616 hasConcept C121332964 @default.
• W4382516616 hasConcept C126322002 @default.
• W4382516616 hasConcept C127413603 @default.
• W4382516616 hasConcept C16568411 @default.
• W4382516616 hasConcept C167135981 @default.
• W4382516616 hasConcept C17923572 @default.
• W4382516616 hasConcept C1862650 @default.
• W4382516616 hasConcept C197934379 @default.
• W4382516616 hasConcept C2778114629 @default.
• W4382516616 hasConcept C2778163477 @default.
• W4382516616 hasConcept C2780072125 @default.
• W4382516616 hasConcept C2780400711 @default.
• W4382516616 hasConcept C2780645631 @default.
• W4382516616 hasConcept C2780739214 @default.
• W4382516616 hasConcept C2780745583 @default.
• W4382516616 hasConcept C500558357 @default.
• W4382516616 hasConcept C61511704 @default.
• W4382516616 hasConcept C71924100 @default.
• W4382516616 hasConcept C77350462 @default.
• W4382516616 hasConcept C78519656 @default.
• W4382516616 hasConceptScore W4382516616C118552586 @default.
• W4382516616 hasConceptScore W4382516616C120665830 @default.
• W4382516616 hasConceptScore W4382516616C121332964 @default.
• W4382516616 hasConceptScore W4382516616C126322002 @default.
• W4382516616 hasConceptScore W4382516616C127413603 @default.
• W4382516616 hasConceptScore W4382516616C16568411 @default.
• W4382516616 hasConceptScore W4382516616C167135981 @default.
• W4382516616 hasConceptScore W4382516616C17923572 @default.
• W4382516616 hasConceptScore W4382516616C1862650 @default.
• W4382516616 hasConceptScore W4382516616C197934379 @default.
• W4382516616 hasConceptScore W4382516616C2778114629 @default.
• W4382516616 hasConceptScore W4382516616C2778163477 @default.
• W4382516616 hasConceptScore W4382516616C2780072125 @default.
• W4382516616 hasConceptScore W4382516616C2780400711 @default.

• next